Andon Health Co., Ltd. (002432.SZ) Latest Company News

Oct 29, 2026, 11:44 UTC
Andon Health reported first-three-quarter 2026 revenue of RMB 806 million, down 24.67% year over year, and net profit of RMB 5.205 billion, up 227.57%.
Source:
- finance.sina.cn
Oct 29, 2026, 11:44 UTC
Andon Health reported third-quarter 2026 revenue of RMB 274 million, down 9.80% year over year, and net profit of RMB 2.135 billion, up 219.21%.
Source:
- finance.sina.cn
Oct 12, 2026, 08:54 UTC
Tianjin Ji'an Medical announced that the National Association of Financial Market Institutional Investors had registered up to RMB 5 billion in debt financing instruments for the company.
Source:
- finance.sina.cn
Sep 18, 2026, 02:33 UTC
RISC-V cloud AI chip company EVAS Intelligence completed a new funding round of nearly RMB 2 billion, with post-money valuation estimated near RMB 15 billion, backed by more than 20 investors including Huatai Innovation, Zhongding Capital, SMIC Capital, and Jiuan Medical.
Source:
- finance.sina.cn
- techtimes.com
Sep 8, 2026, 12:22 UTC
Jiuan Medical announced that shareholder Sanhe Company's stake was passively diluted from 25.07% to 25.00% due to an increase in total shares from stock option exercises between September 27, 2025 and September 4, 2026.
Source:
- finance.sina.cn
Aug 3, 2026, 08:53 UTC
Jiuan Medical announced that as of the end of July 2026, it had not yet sold its repurchased shares; the sale plan was approved on April 30, 2026, with up to 9.295 million shares to be sold during the period from May 28 to November 20, 2026.
Source:
- finance.sina.cn

002432.SZ

Andon Health reported first-three-quarter 2026 revenue of RMB 806 million, down 24.67% year over year, and net profit of RMB 5.205 billion, up 227.57%.

Andon Health reported third-quarter 2026 revenue of RMB 274 million, down 9.80% year over year, and net profit of RMB 2.135 billion, up 219.21%.

Tianjin Ji'an Medical announced that the National Association of Financial Market Institutional Investors had registered up to RMB 5 billion in debt financing instruments for the company.

RISC-V cloud AI chip company EVAS Intelligence completed a new funding round of nearly RMB 2 billion, with post-money valuation estimated near RMB 15 billion, backed by more than 20 investors including Huatai Innovation, Zhongding Capital, SMIC Capital, and Jiuan Medical.

Jiuan Medical announced that shareholder Sanhe Company's stake was passively diluted from 25.07% to 25.00% due to an increase in total shares from stock option exercises between September 27, 2025 and September 4, 2026.

Jiuan Medical announced that as of the end of July 2026, it had not yet sold its repurchased shares; the sale plan was approved on April 30, 2026, with up to 9.295 million shares to be sold during the period from May 28 to November 20, 2026.